Almanack Investment Partners’s MaxCyte MXCT Stock Holding History

Almanack Investment Partners’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-664	Closed	-$4K	–	807
2022 Q3	$4K	Buy	+664	New	+$3.7K	﹤0.01%	633

Other funds holding MXCT

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $159M AUM 139.66% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Almanack Investment Partners's MXCT Position: Q4 2022 in Review

Almanack Investment Partners sold out of MaxCyte (MXCT) in Q4 2022, closing a stake of 664 shares — an estimated $4K sold.

Almanack Investment Partners first reported a position in MXCT in Q3 2022 and held it in 1 quarter. The position peaked at $4K in Q3 2022. 104 funds tracked by Wall St. Rank hold MXCT as of Q4 2022.

Almanack Investment Partners reported no remaining MaxCyte position as of Q4 2022 after selling out during the quarter.
Almanack Investment Partners sold 664 MaxCyte shares in Q4 2022, an estimated $4K.
Almanack Investment Partners first reported a position in MaxCyte in Q3 2022 and held it in 1 quarter.
Almanack Investment Partners's MaxCyte position peaked at $4K in Q3 2022.
104 funds tracked by Wall St. Rank held MaxCyte as of Q4 2022.

Based on Almanack Investment Partners's 13F filing for Q4 2022, filed 9 Feb 2023.